Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jose A. Vazquez has a total of 107 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Trial Endpoints for Candidemia and Invasive Candidiasis: Consensus Recommendations by the Mycoses Study Group Education & Research Consortium and European Confederation of Medical Mycology

    by Jose A Vazquez, Sharon C A Chen, Shmuel Shoham, Julie M Steinbrink, John Baddley, Patricia Munoz, Juergen Prattes, Indira Berrio, Thomas J Walsh, Andreas Groll, et al.

    Invasive candidiasis (IC) remains the most common invasive mycosis world-wide, responsible for a wide range of infections that can range from superficial mucosal infections to life-threatening systemic diseases. Clinical trials of antifungal agents for IC are pivotal to its management. Therapeutic responses in these trials are currently based on consensus criteria initially presented by the Mycoses Study Group (MSG) and the European Organization for Research and the Treatment of Cancer (EORTC) in 2008. These 2008 definitions originally described by Segal et al are still employed by both investigators and regulatory agencies when evaluating antifungal drug efficacy and patient outcomes. However, advances in clinical mycology, the change in epidemiology of Candida infections due to the increase in non-albicans Candida species, and the increase in newer antifungal agents currently under development require a revision of these criteria to ensure appropriate and standardized adjudication of patient outcomes and to accurately capture responses to newer therapeutic regimens and modern interventions. Therefore, the European Confederation of Medical Mycology (ECMM) and Mycoses Study Group Education and Research Consortium (MSGERC) have decided to revise the criteria to be used for future studies.

  • Open Access

    Revised Consensus Clinical Trial Response Criteria by the Mycoses Study Group Education & Research Consortium and European Confederation of Medical Mycology

    by Martin Hoenigl, George R Thompson, Peter G Pappas, Oliver A Cornely, John R Perfect, Neil A R Gow, Dimitrios P Kontoyiannis, Cornelia Lass-Flörl, Johan Maertens, Monica A Slavin, et al.

    Invasive fungal diseases remain a significant cause of patient morbidity and mortality. Improvement in clinical outcomes have been the result of progress in risk stratification, diagnostics, adjunctive care, antifungal therapy, and/or prophylaxis. Yet significant challenges remain, requiring the development of novel treatment strategies. Outcome evaluation in most mycology clinical trials is currently based on consensus criteria published in 2008. However, advances in diagnosis and management of various mycoses and the ever-expanding population of patients at risk necessitate a revision and refinement of these criteria. Appropriate categorization of antifungal treatment response is crucial in assessing the effects of new therapeutic interventions. An international expert panel nominated by the European Confederation of Medical Mycology (ECMM) and Mycoses Study Group Education and Research Consortium (MSGERC) was convened to update the current outcome evaluation criteria. The panel achieved consensus on updated guidelines for assessing treatment responses and defining study outcomes in clinical trials of aspergillosis and other mold diseases, invasive candidiasis, cryptococcosis, and dimorphic fungi in both adults and children. This summary manuscript provides details on the methods, outlines key changes in the criteria, and discusses the next steps and areas for future research.

  • Open Access

    The Upcoming Antifungal Drugs in Clinical Development for the Treatment of Invasive Candidiasis

    by Anna Zubovskaia, Jose Vazquez

    Background: Invasive candidiasis (IC) is a major cause of morbidity and mortality among hospitalized patients, and treatment success relies on early diagnosis and prompt initiation of an appropriate antifungal agent. The increasing rates of resistance to first-line antifungal agents (azoles, echinocandins, and polyenes), along with changes in the epidemiology of IC and the spread of multidrug-resistant C. auris, pose further challenges for the management of IC. Limited therapeutic options and routes of administration, drug–drug interactions, and drug toxicities of commonly utilized antifungals further complicate management in the acute hospital setting and create barriers for long-term outpatient treatment. This article provides a review of the current literature on the upcoming antifungal agents that are being actively investigated as treatment options for invasive candidiasis, including those in early- and late-stage clinical development. Areas Covered: We will discuss the spectrum of activity of novel antifungal agents, mechanisms or resistance, pertinent in vivo and vitro data, as well as data from the clinical trials evaluating efficacy and safety of novel antifungals. Expert Opinion: Rezafungin holds promise as an excellent option for outpatient antimicrobial therapy programs due to its favorable safety profile and convenient once-weekly dosing. Ibrexafungerp has broad-spectrum antifungal activity, including activity against fluconazole- and echinocandin-resistant Candida spp. and is available in an oral formulation, making it an attractive option for step-down therapy after treatment with echinocandins or as an alternative to echinocandins. Fosmanogepix has a novel mechanism of action, a favorable side-effect profile, and a broad spectrum of clinical activity. However, further data from clinical trials are necessary to further establish its role in the management of invasive candidiasis. The role of agents in early clinical development, including BAL2062 and ATI2307, as well as repurposed agents with antifungal activity, such as miltefosine, in the management of invasive candidiasis remains to be determined.


  • Open Access

    Rezafungin Utilisation in Real Life—FungiScope Results From Europe and the United States

    by Ilana Reinhold, Giovanni Mori, Massimiliano Lanzafame, Alessandro Limongelli, Antonio Vena, Julia Götz, Stilla Bauernfeind, Frank Hanses, Lukas Tometten, Michael Mayer, et al.

    Background: Rezafungin, a novel echinocandin with once‐weekly intravenous dosing, offers potential advantages for outpatient parenteral antifungal therapy (OPAT) in invasive candidiasis (IC). While clinical trial data support its efficacy and safety, real‐world experience remains limited.Methods: A retrospective analysis of patients treated with rezafungin across Germany, Italy, Spain, and the United States between January 2024 and June 2025 was conducted. Data was collected via the FungiScope registry. Clinical characteristics, indications for rezafungin, outcomes, safety, and logistical aspects of administration were evaluated.Results: Fifteen patients were included, fourteen with IC; one with chronic pulmonary aspergillosis. Regarding patients with IC, the median age was 65.5 years; 43% were female. The most frequently identified pathogens were Candida glabrata (57%) and Candida parapsilosis (21%). Primary indications for rezafungin were intravascular (36%) and osteoarticular infections (36%). Rezafungin was mainly selected to enable OPAT (86%) or due to fluconazole resistance (36%) or drug–drug interactions (14%). The median treatment duration was 9 weeks (range: 1–38 weeks). One mild adverse event occurred (cutaneous photosensitivity), but rezafungin was otherwise well tolerated. Complete clinical or mycological response was observed in 36% at day 30, and partial response in 50% of patients. Access differed substantially across centres due to administrative and reimbursement hurdles, affecting treatment transition to rezafungin in 71% of patients with IC.Conclusions: Rezafungin was effective and well tolerated in this cohort, particularly in patients requiring long‐term treatment. Administrative and logistical hurdles remain significant barriers to its widespread use. Facilitated access and enhanced awareness may improve patient outcomes by supporting early initiation and continuity of care.


  • Open Access

    Invasive Candidiasis in the Intensive Care Unit: Where Are We Now?

    by Jose A. Vazquez, Lissette Whitaker, Ana Zubovskaia

    Invasive fungal infections in the intensive care unit (ICU) are not uncommon and most cases are caused by Candida species, specifically Candida albicans. However, recently, there has been an increase in non-albicans Candida spp. (C. glabrata; C. parapsilosis) causing invasive fungal infections. This has led to an increasing awareness of this infection due to the increase in documented antifungal resistance in many of these Candida species. In addition, manifestations of invasive candidiasis are often non-specific, and the diagnosis remains extremely challenging. Unfortunately, delays in antifungal therapy continue to hamper the morbidity; length of stay; and the mortality of these infections. Although the echinocandins are the drugs of choice in these infections, antifungal resistance among the non-albicans species (C. glabrata; C. krusei; C. auris; C. parapsilosis) is being observed more frequently. This has led to an increase in morbidity and mortality, specifically in critically ill patients. Overall, the diagnosis and management of invasive candidiasis in the ICU remain challenging. It is imperative that the critical care physician keeps this infection at the forefront of their differential diagnosis in order to decrease the mortality rate of these individuals. In this review, we discuss the current epidemiologic trends, diagnosis, and management of invasive candidiasis in the intensive care unit setting.


  • Open Access

    Chronic Cavitary Pulmonary Histoplasmosis–Novel Concepts Regarding Pathogenesis

    by John F. Fisher, Michael Saccente, George S. Deepe, Natasha M. Savage, Wajih Askar, Jose A. Vazquez

    Because the apices of the lungs are most commonly involved in chronic cavitary histoplasmosis (CCPH), it has been assumed by many to have a pathogenesis which is similar to post-primary tuberculosis. Fungi such as Aspergillus may colonize pulmonary bullae. Although less common, colonization by Histoplasma capsulatum in a heavily endemic area is possible or even probable. In chronic obstructive pulmonary disease (COPD), apical bullae are characteristic. Since COPD is common and CCPH is rare, the pathogenesis of CCPH remains incompletely understood. What is presently known about the pathogenesis of CCPH has not changed appreciably since 1976. A cellblock from a patient with CCPH was analyzed with histochemical stains for T cells, B cells, plasma cells, and macrophages to better understand the pathogenesis of CCPH. The pathogenesis of cavitary disease in histoplasmosis has been assumed to resemble that of tuberculosis. However, liquefaction of a caseous focus in lung apices which resulted from blood-borne tubercle bacilli is distinctly unlike CCPH, as caseation is unusual. Rather, repeated colonization of the apical and other bullae by propagules (microconidium, macroconidium, hyphal fragment) of H. capsulatum in patients with COPD who have resided in heavily endemic areas appears to be the primary event in CCPH. Immunohistochemical enumeration of specific cell types in a patient with CCPH has not been previously carried out to our knowledge, but is only a first step in understanding the disease. In future studies, identification of the varieties of macrophages and cytokines in CCPH may reveal whether the process is pro-inflammatory, anti-inflammatory, or both.


  • Open Access

    Invasive Aspergillosis in the Intensive Care Unit

    by Anna Zubovskaia, Jose A. Vazquez

    Invasive aspergillosis (IA) is a fungal infection, which has traditionally been associated with neutropenia and immunosuppressive therapies. Our understanding of invasive aspergillosis has been evolving and, in the past few decades, IA among ICU patients has been recognized as a common infection and has become more widely recognized. The diagnosis and management of invasive aspergillosis in the ICU is particularly challenging, due to the unstable clinical condition of the patients, lack of diagnostic markers, increased risk of further clinical deterioration, multiple comorbidities, and a need for early assessment and treatment. In this article, we will discuss the challenges and pitfalls of the diagnosis and management of invasive aspergillosis in an ICU setting, along with a review of the current literature that is pertinent and specific to this population.


  • Open Access

    Treatment Outcomes Among Patients With a PositiveCandidaCulture Close to Randomization Receiving Rezafungin or Caspofungin in the ReSTORE Study

    by Alex Soriano, Patrick M Honore, Oliver A Cornely, Methee Chayakulkeeree, Matteo Bassetti, Huang Haihui, Hervé Dupont, Young Keun Kim, Marin Kollef, Bart Jan Kullberg, et al.

    Background: Rezafungin, a novel, once-weekly echinocandin for the treatment of candidemia and/or invasive candidiasis (IC) was noninferior to caspofungin for day 30 all-cause mortality (ACM) and day 14 global cure in the phase 3 ReSTORE trial (NCT03667690). We conducted preplanned subgroup analyses for patients with a positive culture close to randomization in ReSTORE.Methods: ReSTORE was a multicenter, double-blind, double-dummy, randomized trial in patients aged ≥18 years with candidemia and/or IC treated with once-weekly intravenous rezafungin (400 mg/200 mg) or once-daily intravenous caspofungin (70 mg/50 mg). This analysis comprised patients with a positive blood culture drawn between 12 hours before and 72 hours after randomization or a positive culture from another normally sterile site sampled between 48 hours before and 72 hours after randomization. Efficacy endpoints included day 30 ACM, day 14 global cure rate, and day 5 and 14 mycological response. Adverse events were evaluated.Results: This analysis included 38 patients randomized to rezafungin and 46 to caspofungin. In the rezafungin and caspofungin groups, respectively, day 30 ACM was 26.3% and 21.7% (between-group difference [95% confidence interval], 4.6% [−13.7%, 23.5%]), day 14 global response was 55.3% and 50.0% (between-group difference, 5.3% [−16.1%, 26.0%]), and day 5 mycological eradication was 71.1% and 50.0% (between-group difference, 21.1% [−0.2%, 40.2%]). Safety was comparable between treatments.Conclusions: These findings support the efficacy and safety of rezafungin compared with caspofungin for the treatment of candidemia and/or IC in patients with a positive culture close to randomization, with potential early treatment benefits for rezafungin.


  • Efficacy of biofilm disrupters against Candida auris and other Candida species in monomicrobial and polymicrobial biofilms

    by Claudia A. Cox, Elias K. Manavathu, Sushama Wakade, Matthew Myntti, Jose A. Vazquez

    Candida species are now considered global threats by the CDC and WHO. Candida auris specifically is on the critical pathogen threat list along with Candida albicans. In addition, it is not uncommon to find Candida spp. in a mixed culture with bacterial organisms, especially Staphylococcus aureus producing polymicrobial infections. To eradicate these organisms from the environment and from patient surfaces, surface agents such as chlorhexidine (CHD) and Puracyn are used. Biofilm disrupters (BDs) are novel agents with a broad spectrum of antimicrobial activity and have been used in the management of chronic wounds and to sterilise environmental surfaces for the past several years. The goal of this study was to evaluate BDs (BlastX, Torrent, NSSD) and CHD against Candida spp. and S. aureus using zone of inhibition assays, biofilm and time‐kill assays. All BDs and CHD inhibited C. auris growth effectively in a concentration‐dependent manner. Additionally, CHD and the BDs showed excellent antimicrobial activity within polymicrobial biofilms. A comparative analysis of the BDs and CHD against C. auris and C. albicans using biofilm kill‐curves showed at least 99.999% killing. All three BDs and CHD have excellent activity against different Candida species, including C. auris. However, one isolate of C. auris in a polymicrobial biofilm assay showed resistance/tolerance to CHD, but not to the BDs. The fungicidal activity of these novel agents will be valuable in eradicating surface colonisation of Candida spp, especially C. auris from colonised environmental surfaces and from wounds in colonised patients.


  • Infections Due to Non-Candidal Yeasts

    by Rhonda E. Colombo, Jose A. Vazquez